Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 443 results for "zydus group"

Zydus to make presentation on Saroglitazar at Keystone Symposium
Business Standard India

Zydus Cadila to make presentation on Saroglitazar at Keystone ...

AHMEDABAD: Zydus Cadila group will be making an oral presentation on Saroglitazar, a novel compound under development for treatment in Non-alcoholic Steatohepatitis (NASH), at the Keystone Symposium on Liver Metabolism and Non-alcoholic Fatty Liver ... Times of India, 3 weeks ago
[x]  
Indian Express

Zydus, Torrent among top donors to Cong, NCP in 2014 elections

Corporate majors like Cadila Healthcare Ltd and Torrent Group were among the top donors from Gujarat to have contributed to the election kitty of Indian National Congress (INC) and Nationalist Congress Party (NCP) for the 2014 Lok Sabha elections. ...
 Hindu Business Line2 months ago CADILA HEALTHCARE : Torrent, Cadila among donors to Cong, NCP  4 Traders2 months ago Torrent Group & Cadila Healthcare among top political donors from Gujarat during 2013-14  Indian Express2 months ago Torrent Group, Cadila Healthcare among top political donors from Gujarat; BJP only defaulter  Financial Express2 months ago

Zydus begins Phase - III study of Saroglitazar in NASH, a liver disease caused by obesity, diabetes and lipid disorders

Details Category: Small Molecules Published on Sunday, 11 January 2015 21:06 Hits: 45 January 9, 2015 I The Zydus group announced the initiation of Phase III clinical trials to study its effect in adult nonalcoholic steatohepatitis (NASH) ...
 PipelineReview1 month ago

Buy Cadila Healthcare; target Rs 1727: Firstcall Research

Firstcall Research's report on Cadila Healthcare For the 3rd quarter ended Dec 31st, 2014, Zydus Cadila reported Net sales of Rs 21894.60 mn, up by 16.98% from Rs. 18716.90 mn in the corresponding quarter of the previous year on a consolidated ...
 Moneycontrol.com1 week ago Buy Cadila Healthcare; target of Rs 1715: Firstcall  Moneycontrol.com2 months ago

Zydus completes single rising dose Phase I studies for its oral HIF inhibitor, ZYAN1 for treating Anemia and initiates multiple dosing studies

Details Category: Small Molecules Published on Monday, 16 February 2015 12:51 Hits: 46 ZYAN1 is an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, designed to increase the natural production of erythropoietin ...
 PipelineReview2 weeks ago

Zydus Cadila Net Profit up by 52% in Q3

For the third quarter ended 31st December 2014, Cadila Healthcare Limited registered a Net Profit of Rs. 282 crores, up by 52% from Rs. 186 crores in the corresponding period last year. The company registered a Total Income from Operations of Rs.
 FiercePharma3 weeks ago Hexaware Q4 Net Profit Declines 15% to Rs 87 Crore  24Dunia3 weeks ago

Zydus site clears data integrity hurdle in FDA audit?

GMT 2015 Informa plc. All rights reserved. This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT ...
 Scrip1 month ago

Torrent Pharmaceuticals : Pharma inks pact with Reliance for 3 biosimilars

Ahmedabad: City-based Torrent Pharmaceuticals , a part of the Sudhir Mehta -led Torrent group, has entered into an exclusive licensing agreement with Reliance Life Sciences for marketing three biosimilars - Rituximab, Adalimumab and Cetuximab - in ...
 4 Traders2 months ago Torrent Pharma inks pact with Reliance for 3 biosimilars [DNA : Daily News & Analysis (India)]  Pharmacy Choice2 months ago

Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts'

(GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/3fs8dg/the_generic_drugs ) has announced the addition of SNS Research's new report "The Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & ...
 RCL Advisors14 hours ago Research and Markets: Global Preventable Vaccines Market 2015-2019  Tamar Securities6 days ago Global Preventable Vaccines Market 2015-2019 with GlaxoSmithKline, Merck, Novartis, Pfizer & Sanofi Dominating  Biotechgate6 days ago Preventable Vaccines Market to Grow at 10.16% CAGR by 2019 Says a New Research Report at Sandlerresearch.org  RCL Advisors1 week ago
[x]  

India Food Additives Market Forecast and Opportunities, 2020

Indian food additives market is forecast to see a CAGR of 12% until 2020 India has been one of the major markets for food and beverages worldwide due to a large population base and culturally-diverse food habits of people. The country's food and ...
 companiesandmarkets.com7 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less